MedPath

BioMimetix JV, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

9

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:4
Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials

Phase 2
5 (55.6%)
Phase 1
4 (44.4%)

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Phase 1
Not yet recruiting
Conditions
Ovarian Neoplasms
Endometrial Cancer, Endometrial Neoplasm
Interventions
First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
BioMimetix JV, LLC
Target Recruit Count
27
Registration Number
NCT06620029
Locations
🇺🇸

Duke Cancer Institute, Durham, North Carolina, United States

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Phase 2
Terminated
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2022-08-08
Last Posted Date
2024-04-18
Lead Sponsor
BioMimetix JV, LLC
Target Recruit Count
103
Registration Number
NCT05491447
Locations
🇺🇸

Cahaba Dermatology & Skin Health Center, Birmingham, Alabama, United States

🇺🇸

Dermatology Trial Associates, Bryant, Arkansas, United States

🇺🇸

Johnson Dermatology, Fort Smith, Arkansas, United States

and more 16 locations

Trial of BMX-001 or Placebo in Head and Neck Cancer Patients

Phase 2
Withdrawn
Conditions
Head and Neck Cancer
Interventions
Radiation: Radiation Therapy
Other: Placebo
First Posted Date
2020-10-29
Last Posted Date
2021-10-11
Lead Sponsor
BioMimetix JV, LLC
Registration Number
NCT04607642

Evaluation of Topical Application of BMX-010 in Subjects With Rosacea

Phase 2
Suspended
Conditions
Rosacea
Interventions
First Posted Date
2018-11-28
Last Posted Date
2022-09-28
Lead Sponsor
BioMimetix JV, LLC
Target Recruit Count
60
Registration Number
NCT03756389
Locations
🇺🇸

Colorado Skin Care, Englewood, Colorado, United States

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

Phase 2
Terminated
Conditions
Acne Vulgaris
Interventions
Drug: BMX-010 0.3%
First Posted Date
2018-11-23
Last Posted Date
2023-09-21
Lead Sponsor
BioMimetix JV, LLC
Target Recruit Count
2
Registration Number
NCT03752242
Locations
🇺🇸

Colorado Skin Care, Englewood, Colorado, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath